Small Cell Lung Carcinoma

Oncology·MeSH: Small Cell Lung Carcinoma

Prevalence

0.1 / 100K

17 drugs in development·9 companies·13 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
azd9291 80 mg/40 mg	ASTRAZENECA PLC (AZN)
MK-4830	Merck & Co., Inc. (MRK)
open-label azd9291 80 mg/40 mg	ASTRAZENECA PLC (AZN)
osimertinib 80 mg/40 mg	ASTRAZENECA PLC (AZN)
Pemetrexed Disodium	ENANTA PHARMACEUTICALS INC (ENTA)
Topotecan	Merus N.V. (MRUS)

Phase 2(2)

Drug	Company
Budigalimab	AbbVie Inc. (ABBV)
erlotinib	CG Oncology, Inc. (CGON)

Phase 1(6)

Drug	Company
111in-etn029	NOVARTIS AG (NVSEF)
111in-etn029	Novartis AG (NVS)
225ac-etn029	NOVARTIS AG (NVSEF)
225ac-etn029	Novartis AG (NVS)
BI 764532	Merus N.V. (MRUS)
EB-SELECT Single-Target CAR-NK Cells	Merus N.V. (MRUS)

Phase 2/Phase 3(1)

Drug	Company
Pemetrexed	AbbVie Inc. (ABBV)

Phase 4(2)

Drug	Company
bms-986489	BRISTOL MYERS SQUIBB CO (BMY)
Single agent chemotherapy	Merus N.V. (MRUS)

BioSniper tracks 17 drugs in development for Small Cell Lung Carcinoma across 9 companies.

There are 13 clinical trials targeting Small Cell Lung Carcinoma tracked by BioSniper.

The estimated prevalence of Small Cell Lung Carcinoma is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.